Skip to main content

Table 6 HPV Seroprevalence among women with and without invasive cervical cancer

From: Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review

Author Area, subjects Study design HPV test HPV seroprevalence for any and type specific genotypes HPV seroprevalence of any and type specific genotypes among HIV positive women Comments
Newton, et al., 2004) [27] Mulago hospital, 191 cervical cancer cases and 336 controls; 15 years and older with a new diagnosis of cancer from the wards or outpatient clinics between 1994 and 1998. Case Control HPV L1 VLP/ELISA Cases
Type-specific genotypes a
HPV 16, 27%
HPV 18, 7%
HPV 45, 9%
Controls
Any of 3 HPV typesa, 17%
Type-specific genotypes a
HPV 16, 11%
HPV 18, 5%
HPV 45, 6%
HIV Positive Controls
Any of 3 HPV typesa, 22% Type-specific genotypesa
HPV 16, 16%
HPV18, 7%
HPV 45, 8%
Antibodies against HPV 16 were significantly associated with cervical cancer OR* = 2.0 (1.2-3.1)
The risk increased with increasing anti-HPV 16 antibody titre (Ptrend = 0.01)
Namujju, et al., 2010 [26] Naguru and Nsambya Health Centers in Kampala, 2,053 women seeking antenatal services; mean age 23 years (range, 14-48) Cross-sectional Serology/VLP ELISA (6, 11, 16,18,31, 33, 45) Any of the 7 selected HPV typesa, 57%   HIV prevalencea, 7.0%
  1. aDenominator consist of all tested women
  2. OR* = Odds Ratio